TH-302: Additional Phase I/II data

Additional data from 45 evaluable patients in the dose-escalation Phase I part of the U.S. Phase I/II TH-CR-402 trial showed that 240-575 mg/m 2 weekly IV TH-302 in combination with one of Gemzar, A...